Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Ciliated Cell Disorders and Oncology Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for CCDC112 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CCDC112 Recombinant Protein High purity (>95%), Endotoxin Controlled. Sequence Verified. Theoretical MW optimized for assay stability. |
View CCDC112 Products |
| Gene Delivery | CCDC112 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and localization assays. |
View CCDC112 Products |
| Benchmark Ab | Anti-CCDC112 Recombinant Antibody Recombinant positive control for Western Blot, IHC, and Flow Cytometry. |
View CCDC112 Products |
| Validator | CCDC112 siRNA Set For target knockdown verification and functional validation. |
View CCDC112 Products |
| Related Target A | CEP290 Centrosomal protein partner involved in ciliogenesis and ciliary transport pathways. |
View CEP290 Products |
| Related Target B | CCDC6 Coiled-coil family control for specificity screening and off-target evaluation. |
View CCDC6 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Coiled-coil aggregation and solubility issues | Sequence-verified constructs optimized for soluble expression and structural integrity. |
| Subfamily off-target cross-reactivity | CCDC family homolog proteins available for rigorous counter-screening panels. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included |
| False Positives | Validated siRNA included for specificity checks |
Live CCDC112 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CCDC112 therapeutics is intensifying, with major players shifting focus from traditional mAbs to intracellular modulation and RNA-based therapeutics. As first-generation therapies reach the clinic, the next wave of R&D is targeting the disruption of coiled-coil protein-protein interactions (PPIs) and centrosomal localization pathways in solid tumors and ciliopathies.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (PPI Inhibitor) | Academic Consortia, Biotech Startups | Gastric Cancer, Ciliopathies | Protein-Protein Interaction Assay (Need high-purity, non-aggregated CCDC112 protein) |
| Lentiviral Gene Therapy | Gene Therapy Specialists | Retinal Degeneration, Ciliary Dyskinetic Syndromes | Transduction Validation (Need stable expression tracking and validated antibodies) |
| siRNA / RNAi | RNA Therapeutics Innovators | Oncology (Overexpressing Tumors) | Knockdown Verification (Need sequence-specific siRNA and Western Blot controls) |